Daiichi Sankyo (OTCMKTS:DSNKY) Stock Price Up 0.6% - Here's Why

Key Points

• Daiichi Sankyo's stock price increased by 0.6%, reaching a last traded price of $24.78, despite a 40% drop in trading volume compared to its average.
• Nomura Securities upgraded Daiichi Sankyo to a "strong-buy" rating, signaling positive growth expectations from analysts.
• The company has a market capitalization of $46.94 billion and maintains solid financial ratios, including a current ratio of 2.53.

Shares of Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) rose 0.6% during trading on Monday . The company traded as high as $24.79 and last traded at $24.78. Approximately 139,943 shares changed hands during trading, a decline of 40% from the average daily volume of 231,911 shares. The stock had previously closed at $24.63.

Wall Street Analyst Weigh In

Separately, Nomura Securities raised shares of Daiichi Sankyo to a "strong-buy" rating in a research report on Friday, June 6th.

Daiichi Sankyo Stock Performance

The stock's 50-day moving average price is $23.91 and its 200-day moving average price is $24.37. The company has a market cap of $46.14 billion and a P/E ratio of 23.65. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.53 and a quick ratio of 1.85.

Daiichi Sankyo Company Profile

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.